Psych Capital Plc Logo

Psych Capital Plc

Biopharmaceutical company developing psilocybin-based therapy for anorexia nervosa.

PSY | IL

Overview

Corporate Details

ISIN(s):
GB00BL6CJQ54
LEI:
213800WXCQ1C6GPLHH68
Country:
United Kingdom
Address:
17 HANOVER SQUARE, W1S 1BN LONDON

Description

Shortwave Life Sciences Plc, formerly Psych Capital Plc, is a biopharmaceutical company that originates and develops innovative treatments for mental healthcare. The company's primary clinical program focuses on developing a psilocybin-based therapy for anorexia nervosa, a condition with no currently approved medication. It employs an IP-driven approach, leveraging global partnerships and an experienced leadership team to optimize its drug discovery and development processes. Through its subsidiary, Blossom Analysis, the company also provides a data and insights platform for the psychedelic healthcare industry.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-12-02 11:35
Symposium: Shortwave Presenting Clinical Research
English 11.5 KB
2025-12-02 08:25
Result of AGM, TVR and Shares Correction
English 8.2 KB
2025-11-06 08:25
Patent Application Publication
English 13.4 KB
2025-11-04 12:45
AGM, Treasury Policy & Capital Reorganisation
English 44.0 KB
2025-10-31 16:25
ANNUAL REPORT AND ACCOUNTS TO 30 APRIL 2025
English 248.8 KB
2025-09-10 08:00
Direction, Director Changes and Medical Adviser
English 20.9 KB
2025-08-19 13:50
Holding(s) in Company
English 56.0 KB
2025-08-04 12:00
Clarification on Strategic Advisor Appointment
English 6.0 KB
2025-07-29 08:00
£250k Fundraising, New Directors & Review
English 27.3 KB
2025-06-24 14:10
AQSE Only - Holding(s) in Company
English 56.2 KB
2025-06-16 11:21
Holding(s) in Company
English 56.2 KB
2025-01-31 17:52
Interim Results to 31 October 2024
English 115.6 KB
2024-12-23 13:00
Pre-Crowdfunding re Groundbreaking Treatment
English 9.5 KB
2024-11-29 16:16
Total Voting Rights
English 7.2 KB
2024-11-27 15:12
Director Appointment and SPA Update
English 26.7 KB

Automate Your Workflow. Get a real-time feed of all Psych Capital Plc filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Psych Capital Plc

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Psych Capital Plc via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

1NKEMIA Logo
Biotechnology company providing R&D and services for the life sciences sector.
Spain
IKM
2cureX AB Logo
Develops an IVD test using 3D tumoroids to predict patient response to cancer drugs.
Sweden
2CUREX
Abera Bioscience AB Logo
Develops mucosal vaccines using a proprietary Outer Membrane Vesicle (OMV) platform.
Sweden
ABERA
Clinical-stage biopharma developing therapeutics for oncology and viral diseases.
South Korea
203400
ABL Bio Inc. Logo
Develops bispecific antibody therapeutics for oncology and neurodegenerative diseases.
South Korea
298380
Abpro Holdings, Inc. Logo
Clinical-stage biotech developing antibody therapeutics for oncology and ophthalmology.
United States of America
ABP
Absci Corp Logo
A generative AI drug creation company developing biologic medicines.
United States of America
ABSI
Achiko AG Logo
A digital services platform for cross-border business compliance and engagement.
Switzerland
ACHI
Active Biotech Logo
Biotechnology company developing drugs for oncology and inflammatory eye disorders.
Sweden
ACTI
Adagene Inc. Logo
Clinical-stage biotech developing antibody-based immunotherapies for oncology.
United States of America
ADAG

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.